Pillar Biosciences Launches Kitted NGS Panel to Support Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML)
The research-use-only MRDTectTM NPM1 and FLT3 ITD panel is Pillar’s first product to support localized NGS-based MRD testing, uniting ultrasensitive NPM1 and FLT3-ITD detection in a single-tube, DNA-based workflow that laboratories can run in-house NATICK, Mass. — October 22, 2026 — Pillar Biosciences, Inc., a leader in oncology-focused next-generation sequencing (NGS) solutions, today announced the launch […]